TY - JOUR
T1 - Percutaneous arteriovenous fistula creation with the 4F WavelinQ EndoAVF System
AU - WavelinQ 4 French Investigators
AU - Berland, Todd
AU - Clement, Jason
AU - Inston, Nicholas
AU - Kreienberg, Paul
AU - Ouriel, Kenneth
AU - Bala, Saravanan
AU - Benck, Urs
AU - Berland, Todd L.
AU - Brunkwall, Jan
AU - Chan, Tze
AU - Dellanna, Frank
AU - Ebner, Adrian
AU - Gilbert, James
AU - Griffin, Joseph
AU - Haage, Patrick
AU - Kiaii, Mercedeh
AU - Lichtenberg, Michael
AU - Peden, Eric K.
AU - Scheinert, Dierk
AU - Schmitz-Rixen, Thomas
AU - Rosenkranz, Alexander
AU - Schwindt, Arne
AU - Tavakoli, Afshin
AU - Tordoir, Jan
AU - Wadoodi, Ashar
AU - Weiss, Norbert
AU - Westin, Gregory G.
N1 - Funding Information:
The studies were sponsored by TVA Medical, a wholly-owned subsidiary of Becton, Dickinson and Company. Author conflict of interest: K.O. is employed by Syntactx. Syntactx received research funding from the manufacturer of the product for data analysis. J.C. has been paid a consulting fee by TVA and BD. T.B. is a consultant for BD for education and training, but receives no royalties and has no ownership in the company. N.I. has received honoraria from BD Bard for consulting and education, and has no other conflicts to disclose. P.K. has no conflicts of interest to disclose. The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.
Publisher Copyright:
© 2021 The Authors
PY - 2022/3
Y1 - 2022/3
N2 - Background: Percutaneous devices for creation of native arteriovenous fistulae offer an alternative to traditional open surgical techniques. The 4F WavelinQ EndoAVF System was developed as a lower profile alternative to facilitate access through smaller vessels and minimize access site complications; The current report is the original first experience of this device, assessing outcome in 120 patients followed for 6 months. Methods: The use of the 4F WavelinQ system in three studies, EASE (32 patients), EASE-2 (24 patients), and the EU postmarket clinical follow-up study (64 patients) was aggregated and analyzed. Patients were followed with duplex ultrasound at discharge and follow-up visits at 1, 3, and 6 months. Primary, assisted primary, and secondary patency rates were evaluated as Kaplan-Meier estimates and standard errors. Time to maturity and time to successful cannulation were defined as the mean ± standard deviation days from the procedure in patients enrolled on dialysis. Results: Procedural success was achieved in 116 patients (96.7%). Primary, assisted-primary, and secondary 6-month patency rates were 71.9% ± 4.5%, 80.7% ± 4.1%, and 87.8% ± 3.3%, respectively. Time to maturity averaged 41 ± 17 days. Time to successful cannulation averaged 68 ± 51 days. Device-related serious adverse events were reported in 3 of 120 patients (2.5%) and procedure-related serious adverse events occurred in 7 of 120 patients (5.8%). Arterial or venous access complications were not reported in any of the patients. Access circuit reinterventions were performed in 23 patients (19.2%), split between those performed for EndoAVF maturation (13/120 [10.8%]) and maintenance (11/120 [9.2%]). Conclusions: Percutaneous creation of native dialysis fistulae with the 4F WavelinQ EndoAVF System is safe and effective, with favorable durability and a low rate of serious complications and reinterventions through 6-month follow-up. Use of the 4F device allows for percutaneous fistula creation between the radial artery and radial vein or the ulnar artery and ulnar vein. These findings suggest that the 4F device is a useful percutaneous alternative to open surgical AVF or endovascular AVF with larger bore devices.
AB - Background: Percutaneous devices for creation of native arteriovenous fistulae offer an alternative to traditional open surgical techniques. The 4F WavelinQ EndoAVF System was developed as a lower profile alternative to facilitate access through smaller vessels and minimize access site complications; The current report is the original first experience of this device, assessing outcome in 120 patients followed for 6 months. Methods: The use of the 4F WavelinQ system in three studies, EASE (32 patients), EASE-2 (24 patients), and the EU postmarket clinical follow-up study (64 patients) was aggregated and analyzed. Patients were followed with duplex ultrasound at discharge and follow-up visits at 1, 3, and 6 months. Primary, assisted primary, and secondary patency rates were evaluated as Kaplan-Meier estimates and standard errors. Time to maturity and time to successful cannulation were defined as the mean ± standard deviation days from the procedure in patients enrolled on dialysis. Results: Procedural success was achieved in 116 patients (96.7%). Primary, assisted-primary, and secondary 6-month patency rates were 71.9% ± 4.5%, 80.7% ± 4.1%, and 87.8% ± 3.3%, respectively. Time to maturity averaged 41 ± 17 days. Time to successful cannulation averaged 68 ± 51 days. Device-related serious adverse events were reported in 3 of 120 patients (2.5%) and procedure-related serious adverse events occurred in 7 of 120 patients (5.8%). Arterial or venous access complications were not reported in any of the patients. Access circuit reinterventions were performed in 23 patients (19.2%), split between those performed for EndoAVF maturation (13/120 [10.8%]) and maintenance (11/120 [9.2%]). Conclusions: Percutaneous creation of native dialysis fistulae with the 4F WavelinQ EndoAVF System is safe and effective, with favorable durability and a low rate of serious complications and reinterventions through 6-month follow-up. Use of the 4F device allows for percutaneous fistula creation between the radial artery and radial vein or the ulnar artery and ulnar vein. These findings suggest that the 4F device is a useful percutaneous alternative to open surgical AVF or endovascular AVF with larger bore devices.
KW - Arteriovenous fistula
KW - Chronic kidney disease
KW - EndoAVF
KW - Hemodialysis
KW - Percutaneous
UR - http://www.scopus.com/inward/record.url?scp=85123022799&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123022799&partnerID=8YFLogxK
U2 - 10.1016/j.jvs.2021.09.025
DO - 10.1016/j.jvs.2021.09.025
M3 - Article
C2 - 34601046
AN - SCOPUS:85123022799
VL - 75
SP - 1038-1046.e3
JO - Journal of Vascular Surgery
JF - Journal of Vascular Surgery
SN - 0741-5214
IS - 3
ER -